J W CLARK - JoVE Visualize

Showing results (141-150 of 161) with videos related to

Pageof 17

Sort By:

Cancer Research|January 1, 1990

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancerW J Urba, R G Steis, D L Longo, et al.

Clinical Immunology and Immunopathology|July 1, 1990

T-cell subsets in healthy teenagers: transition to the adult phenotypeD J Tollerud, S T Ildstad, L M Brown, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.

Blood|October 1, 1991

Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2aJ W Smith, D L Longo, W J Urba, et al.

Cancer|August 1, 1985

Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virusJ W Clark, B H Hahn, D L Mann, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990

Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinomaR G Steis, J A Carrasquillo, R McCabe, et al.

Blood|November 1, 1988

Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alphaS L Giardina, H A Young, C R Faltynek, et al.

British Journal of Cancer|June 30, 2005

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II studyA Martin, S Nerenstone, W J Urba, et al.

Journal of the National Cancer Institute|June 17, 1992

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.

Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:

Pageof 17

Cancer Research|January 1, 1990

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancerW J Urba, R G Steis, D L Longo, et al.

Clinical Immunology and Immunopathology|July 1, 1990

T-cell subsets in healthy teenagers: transition to the adult phenotypeD J Tollerud, S T Ildstad, L M Brown, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2001

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignanciesD P Ryan, J G Supko, J P Eder, et al.

Blood|October 1, 1991

Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2aJ W Smith, D L Longo, W J Urba, et al.

Cancer|August 1, 1985

Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virusJ W Clark, B H Hahn, D L Mann, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990

Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinomaR G Steis, J A Carrasquillo, R McCabe, et al.

Blood|November 1, 1988

Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alphaS L Giardina, H A Young, C R Faltynek, et al.

British Journal of Cancer|June 30, 2005

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumoursR T Penson, M V Seiden, U A Matulonis, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II studyA Martin, S Nerenstone, W J Urba, et al.

Journal of the National Cancer Institute|June 17, 1992

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.

Pageof 17